Non-Alcoholic Fatty Liver Disease Research Pipeline

According to NIH funding data, a very large amount of public research money has been directed toward Non-Alcoholic Fatty Liver Disease, which tells patients that this condition has been taken seriously as a significant health priority. However, the direction of that funding has been falling year on year, which may signal a shift in research priorities or a maturing of the foundational science. Patients should understand that funding trends can influence how quickly new discoveries move toward clinical testing, so this downward trend is worth watching.

Registry data shows activity across both early and late stage trials, meaning research has progressed well beyond initial safety testing and some treatments are now being evaluated in Phase 3 studies for effectiveness in larger groups of people. The presence of both Phase 1 and late stage trial activity suggests the field is broad, with some experimental approaches still in early exploration while others are much closer to potential regulatory consideration. This spread of activity is generally an encouraging sign that the pipeline contains treatments at multiple stages of development.

For Australian patients, the picture is less clear in practical terms. No TGA approval is currently recorded for treatments specifically targeting this condition, and no PBS listing has been captured in the available data, meaning that even if promising treatments exist overseas, they may not yet be formally approved or subsidised for use in Australia. Patients are encouraged to speak with their specialist about what options may be accessible to them, including whether any Australian clinical trials are open for participation. This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.